(PTH) DWA Healthcare Momentum - Overview
Etf: Healthcare, Momentum, ETF, Nasdaq
Dividends
| Dividend Yield | 3.01% |
| Yield on Cost 5y | 0.49% |
| Yield CAGR 5y | 999.90% |
| Payout Consistency | 14.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 30.3% |
| Relative Tail Risk | 2.93% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | -0.95 |
| Character TTM | |
|---|---|
| Beta | 0.846 |
| Beta Downside | 0.780 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.16% |
| CAGR/Max DD | 0.29 |
Description: PTH DWA Healthcare Momentum January 05, 2026
The Invesco DWA Healthcare Momentum ETF (NASDAQ:PTH) aims to allocate at least 90% of its assets to the securities that make up its underlying index, which consists of a minimum of 30 healthcare companies selected for strong relative-strength or momentum characteristics.
Key metrics to watch include the fund’s 12-month price momentum, which historically averages a 15-20% outperformance versus the broader S&P 500 Health Care Index, and its expense ratio of 0.55%, which is competitive for a sector-focused, actively-managed ETF. Recent sector drivers such as aging demographics, increased biotech R&D spending (up ~8% YoY), and favorable regulatory trends for tele-health services are likely to reinforce the momentum tilt of the holdings.
For a deeper quantitative dive into PTH’s factor exposures and risk profile, you might explore ValueRay’s analytical tools.
What is the price of PTH shares?
Over the past week, the price has changed by +0.89%, over one month by -1.33%, over three months by +5.93% and over the past year by +15.11%.
Is PTH a buy, sell or hold?
What are the forecasts/targets for the PTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 52 | 6.6% |
PTH Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 123.7m USD (123.7m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 123.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 123.7m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.03% (E(123.7m)/V(123.7m) * Re(9.03%) + (debt-free company))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)